Follow
Cancer Treatment
Cancer Treatment: are treatments that may include surgery, chemotherapy, and radiation therapy. If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. Adjuvant treatment.
NOV 14, 2019 | 6:00 AM
Burn patients are at risk for organ dysfunction secondary to “burn shock” and sepsis. The initial 24 hours following major burn injury presents with significant hypotension due to...
NOV 14, 2019 | 6:00 AM
Facioscapulohumeral muscular dystrophy (FSHD), one of the most common forms of progressive muscular dystrophies and is often conventionally diagnosed by Southern blot analysis. The accurate d...
NOV 13, 2019 | 12:00 PM
DATE: November 13, 2019TIME: 12:00pm PT NK cells play a major role in immune surveillance and in the early immune response to cancer and infections. Beneficial anti-tumor respo...
NOV 12, 2019 | 10:00 AM
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
NOV 07, 2019 | 9:00 AM
DATE: November 7, 2019 TIME: 9:00am PST, 12:00pm EST In collaboration with Hematherix and Thermo Fisher, Dr. Laurent Mosnier is investigating a new treatment for acute traumatic bl...
OCT 31, 2019 | 9:00 AM
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
OCT 24, 2019 | 12:00 PM
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
OCT 22, 2019 | 8:00 AM
Calprotectin is a member of the S100 family of calcium binding proteins, being a hetero dimmer of S100A8/9 and accounts for 60% of the protein in the cytoplasm of neutrophils. It is released...
OCT 10, 2019 | 1:30 PM
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
OCT 10, 2019 | 12:00 PM
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
OCT 10, 2019 | 10:30 AM
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
OCT 10, 2019 | 10:30 AM
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
